Casirivimab/imdevimab (REGN-COV2, Ronapreve), a cocktail of human antibodies against the S-protein RBD of SARS-CoV-2, was first authorized by the FAD for emergency use to treat patients with mild-to-moderate COVID-19 [54,55]. This evidence concerns the gene PROS1 and COVID-19.